Baricitinib Intermediate (CAS 1029716-44-6)
Google Keywords: Baricitinib Intermediate, CAS 1029716-44-6, JAK Inhibitor Synthesis, Rheumatoid Arthritis API Intermediates, GMP Pharmaceutical Manufacturing
🌟 Product Overview
Baricitinib Intermediate (CAS 1029716-44-6) is a high-purity chemical intermediate essential for synthesizing Baricitinib, a Janus kinase (JAK) inhibitor approved for treating rheumatoid arthritis and severe inflammatory conditions. This intermediate ensures precision and scalability in API production while adhering to stringent pharmaceutical quality standards.
Primary Function: Acts as a critical building block in the multi-step synthesis of Baricitinib API.
Applications: Rheumatoid arthritis drug development, JAK inhibitor manufacturing, and large-scale API production.
✅ Key Advantages
🔹 Ultra-High Purity | ≥99.0% (HPLC/GC verified) | Complies with ICH Q11 guidelines for intermediates.
🔹 Scalable Synthesis | Optimized for high-yield, cost-effective manufacturing with minimal impurities.
🔹 Regulatory Compliance | Fully characterized by NMR, HRMS, and FTIR to support FDA/EMA submissions and GMP audits.
🧪 Applications
API Production: Enables efficient synthesis of Baricitinib with consistent quality.
Process Optimization: Supports R&D in refining synthetic pathways for improved efficiency.
Quality Control: Used in analytical method validation and batch release testing.
📜 Quality Assurance
Testing Methods: HPLC, GC, NMR, HRMS, and FTIR for structural confirmation and purity analysis.
Standards: Meets USP <1086>, EP 10.0, and ISO 9001:2015 certified manufacturing protocols.
📈 Market Trends
The global rheumatoid arthritis treatment market is projected to exceed $38.5 billion by 2030 (CAGR 5.8%), driven by rising autoimmune disease prevalence and demand for targeted therapies like JAK inhibitors. Baricitinib intermediates are pivotal in accelerating generic and innovative drug development post-patent expiry.
Enhance your JAK inhibitor production with Baricitinib Intermediate – precision-engineered for quality, scalability, and regulatory excellence.
China
